However, compounded GLP-1s are not FDA-approved and, as a result, come with a level of risk
The responses to this question were almost identical to the previous question with the selected symptoms being vomiting (86%, n = 200), nausea (70%, n = 162), fullness (54%, n = 126), bloating (53%, n = 124), then upset stomach (46%, n = 108), lethargy (18%, n = 43), dizziness (14%, n = 32), other (9%, n = 20), loss of appetite (9%, n = 20), none (7%, n = 16), and headache (2%, n = 4) (Tables 6-8)
Bioavailability is a measure of how much of a substance actually enters systemic circulation and is available to have an active effect
Can Changing Pharmacy or Brand of Compounded GLP-1 Affect Response If the new prep is sub-potent or improperly dosed, yes
Evidence level: Moderate - peer-reviewed studies in humans